"NF-kappa B p50 Subunit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A component of NF-kappa B transcription factor. It is proteolytically processed from NF-kappa B p105 precursor protein and is capable of forming dimeric complexes with itself or with TRANSCRIPTION FACTOR RELA. It regulates expression of GENES involved in immune and inflammatory responses.
| Descriptor ID |
D052002
|
| MeSH Number(s) |
D12.776.260.600.124 D12.776.660.600.124 D12.776.930.600.124
|
| Concept/Terms |
NF-kappa B p50 Subunit- NF-kappa B p50 Subunit
- NF kappa B p50 Subunit
- NFKB1 Transcription Factor
- Transcription Factor, NFKB1
- NF-kappa B p50
- NF kappa B p50
- p50, NF-kappa B
- NF-kappaB 50-kDa
- NF kappaB 50 kDa
|
Below are MeSH descriptors whose meaning is more general than "NF-kappa B p50 Subunit".
Below are MeSH descriptors whose meaning is more specific than "NF-kappa B p50 Subunit".
This graph shows the total number of publications written about "NF-kappa B p50 Subunit" by people in this website by year, and whether "NF-kappa B p50 Subunit" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 2 | 1 | 3 |
| 2010 | 0 | 2 | 2 |
| 2011 | 3 | 1 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "NF-kappa B p50 Subunit" by people in Profiles.
-
Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
-
Combined immunodeficiency caused by a novel homozygous NFKB1 mutation. J Allergy Clin Immunol. 2021 02; 147(2):727-733.e2.
-
Advances and highlights in primary immunodeficiencies in 2017. J Allergy Clin Immunol. 2018 10; 142(4):1041-1051.
-
Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol. 2017 06; 18(6):694-704.
-
NF-?B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 06; 30(6):854-876.
-
The Inflammatory Transcription Factors NF?B, STAT1 and STAT3 Drive Age-Associated Transcriptional Changes in the Human Kidney. PLoS Genet. 2015 Dec; 11(12):e1005734.
-
NF-?B directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell. 2014 Oct 23; 56(2):219-231.
-
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014 Jul; 4(7):816-27.
-
a-catenin acts as a tumour suppressor in E-cadherin-negative basal-like breast cancer by inhibiting NF-?B signalling. Nat Cell Biol. 2014 Mar; 16(3):245-54.
-
Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(3):917-24.